Results 81 to 90 of about 4,961 (248)
Annals of Neurology, Volume 97, Issue 6, Page 1205-1214, June 2025.Objectives Intravenous thrombolysis (IVT) is contraindicated for acute ischemic stroke (AIS) patients taking direct oral anticoagulants (DOACs) within 48 hours before index stroke. Limited data exist on off‐label use of IVT for these patients. We compared the safety and outcomes of IVT in AIS patients with DOAC treatment and patients with no OAC before
Marius Matusevicius +11 more
wiley +1 more source
Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis [PDF]
, 2020 Background Application of idarucizumab and hemodialysis are options to reverse the action of the oral anticoagulant dabigatran in emergency situations.
Fuhr, Laura Maria +3 more
core +1 more source
Journal of Clinical Medicine, 2021 Specific antagonists have been developed for the reversal of direct oral anticoagulants (DOAC). We investigated the impact of these reversal agents on the plasma concentration and visco-elastic test results of dabigatran and factor Xa inhibitors.
D. Oberladstätter +6 more
semanticscholar +1 more source
Hong Kong Journal of Emergency Medicine, Volume 32, Issue 2, April 2025.Abstract Objective Currently, there is no consensus among international guidelines on the management of patients with mild traumatic brain injuries (MTBIs) who are on direct oral anti‐coagulants (DOACs). Overuse of computed tomography (CT) scan of the brain results in unnecessary radiation exposure, longer waits and higher costs.
Ho Man Cheng +3 more
wiley +1 more source
Association of Anaesthetists guidelines: the use of blood components and their alternatives
Anaesthesia, Volume 80, Issue 4, Page 425-447, April 2025.Summary Background The administration of blood components and their alternatives can be lifesaving. Anaemia, bleeding and transfusion are all associated with poor peri‐operative outcomes. Considerable changes in the approaches to optimal use of blood components and their alternatives, driven by the findings of large randomised controlled trials and ...
Akshay Shah +12 more
wiley +1 more source
Jefferson Digital Commons quarterly report: October-December 2017 [PDF]
, 2018 This quarterly report includes: Assorted assets added to the JDC in the last quarter Grand Rounds Recordings College Within a College (CWIC) Posters Program of Industrial Design Capstones What people are saying about the ...
Copeland, James, LIBT +2 more
core +1 more source
Interventional radiology treatments for iatrogenic severe bleeding during percutaneous coronary interventions [PDF]
, 2018 Purpose: Interventional cardiology and interventional radiology are separate medical disciplines in which intra-arterial contrast media are used. Interventional cardiology has resigned from many types of treatment techniques that are now used and ...
Brzozowski, Krzysztof +5 more
core +1 more source
Frontiers in Neurology, 2021 Background and Purpose: Idarucizumab achieves instant reversal of anticoagulation and enables intravenous thrombolysis (IVT) in dabigatran-treated acute ischemic stroke (AIS) patients.
Senta Frol +4 more
semanticscholar +1 more source
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. [PDF]
, 2018 Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD).
Amann, Kerstin +48 more
core +3 more sources
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Drug Design, Development and Therapy, 2016 Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous ...
Sié P
doaj